<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00871377</url>
  </required_header>
  <id_info>
    <org_study_id>R21AT003420-01A2</org_study_id>
    <nct_id>NCT00871377</nct_id>
  </id_info>
  <brief_title>Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures</brief_title>
  <acronym>FOS</acronym>
  <official_title>Pilot Randomized Double Blind Crossover Study Of Fish Oil [Eicosapentaenoic Acid (EPA) And Docosahexaenoic Acid (DHA)] For Intractable Partial Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Center for Complementary and Integrative Health (NCCIH)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify
      cardiac risk factors in people with epilepsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epilepsy is a common and disabling condition, characterized by recurrent seizures. Sudden
      unexpected death (SUDEP) is a major cause of mortality in people with epilepsy. SUDEP
      accounts for up to 20% of all cause mortality, and is most common in younger people,
      especially in their 20's to 40's year olds. In those with drug resistant epilepsy, SUDEP is
      five times more common than in well-controlled epilepsy. Likely causes of death include
      cardiac arrhythmias due to impaired autonomic regulation and reduced heart rate variability.
      Similarly, patients with recent myocardial infarction and congestive heart failure are at
      higher risk for sudden death, and manifest markedly reduced heart rate variability. Clinical
      studies of heart disease indicate that n-3 fatty acids, prevent cardiac arrhythmias, reduce
      mortality after myocardial infarction, and reduce the risk of sudden cardiac death. The
      mechanism by which EPA and DHA exert their anti-arrhythmia effect is due to inactivation of
      high frequency sodium and L-type calcium channels in the heart. In addition, n-3 fatty acids
      improve HRV in cardiac patients, and this reduction in HRV is postulated to be a marker of
      the anti-arrhythmic effect of n-3 fatty acids. Preliminary data from our group indicates that
      n-3 fatty acids improve HRV in people with epilepsy, especially those with low HRV (SDNN &lt;
      50). The commonality between n-3 fatty acids and improvement in HRV in patients with heart
      disease and epilepsy serves as a basis for our hypothesis that n-3 fatty acids may reduce the
      risk of SUDEP in epilepsy. The purpose of this proposal is to determine if n-3 fatty acids
      reduce seizures and modify cardiac risk in people with epilepsy who are at risk of SUDEP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizure Frequency</measure>
    <time_frame>Study completion (42 weeks)</time_frame>
    <description>Seizure frequency (seizures per day or seizures per month)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Corn Oil Placebo (n-6 fatty acids)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2160 mg of EPA + DHA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose Fish Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1060 mg of EPA + DHA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>corn oil (n-6 fatty acids)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Corn Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Dose Fish Oil</intervention_name>
    <description>n-3 fatty acids, 1060 mg EPA + DHA</description>
    <arm_group_label>High Dose Fish Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Dose Fish Oil</intervention_name>
    <description>n-3 fatty acids, 2160 mg EPA + DHA</description>
    <arm_group_label>Low Dose Fish Oil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, age 18 - 70

          -  History of intractable localization related/partial onset seizures and generalized
             tonic/clonic or tonic seizures defined according to International League Against
             Epilepsy (ILAE) classification as:

          -  A history compatible with localization related partial epilepsy

          -  A history of generalized tonic clonic or tonic seizures with loss of consciousness

          -  Three or more simple partial, complex partial or tonic-clonic seizures per month

          -  An EEG and/or an MRI consistent with a localization related epilepsy

          -  Evidence of at least three seizures per month for at least two months prior to the
             study

          -  Exposure to at least one antiepileptic drug at adequate dose

        Exclusion Criteria:

          -  Significant or progressive medical, cardiac, or other illness

          -  Allergy to fish products or fish oil

          -  History of a coagulation disorder

          -  History of non-epileptic seizures

          -  Consumption of Fish Oil at any time 30 days or less prior to enrollment

          -  Any change in antiepileptic drugs for 30 days or less prior to enrollment

          -  Treatment with Warfarin for 30 days or less prior to enrollment

          -  Previous poor compliance with therapy

          -  Drug or alcohol abuse

          -  Uncountable seizures as a result of seizure clustering, or inadequate supervision if
             the patient cannot count their own seizures.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher M DeGiorgio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>David Geffen - UCLA School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA General Clinical Research Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.centerwatch.com/clinical-trials/listings/studydetails.aspx?StudyID=140859</url>
    <description>CenterWatch Listing</description>
  </link>
  <reference>
    <citation>DeGiorgio CM, Miller P, Meymandi S, Gornbein JA. n-3 fatty acids (fish oil) for epilepsy, cardiac risk factors, and risk of SUDEP: clues from a pilot, double-blind, exploratory study. Epilepsy Behav. 2008 Nov;13(4):681-4. doi: 10.1016/j.yebeh.2008.08.001. Epub 2008 Sep 7.</citation>
    <PMID>18721899</PMID>
  </reference>
  <reference>
    <citation>DeGiorgio CM, Miller P. n-3 fatty acids (eicosapentanoic and docosahexanoic acids) in epilepsy and for the prevention of sudden unexpected death in epilepsy. Epilepsy Behav. 2008 Nov;13(4):712-3. doi: 10.1016/j.yebeh.2008.06.017. Epub 2008 Aug 9.</citation>
    <PMID>18634902</PMID>
  </reference>
  <results_reference>
    <citation>DeGiorgio CM, Miller P, Meymandi S, Chin A, Epps J, Gordon S, Gornbein J, Harper RM. RMSSD, a measure of vagus-mediated heart rate variability, is associated with risk factors for SUDEP: the SUDEP-7 Inventory. Epilepsy Behav. 2010 Sep;19(1):78-81. doi: 10.1016/j.yebeh.2010.06.011. Epub 2010 Jul 27.</citation>
    <PMID>20667792</PMID>
  </results_reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2009</study_first_submitted>
  <study_first_submitted_qc>March 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2009</study_first_posted>
  <results_first_submitted>October 31, 2013</results_first_submitted>
  <results_first_submitted_qc>January 8, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2014</results_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Center for Complementary and Integrative Health (NCCIH)</investigator_affiliation>
    <investigator_full_name>DeGiorgio, Chris</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>cardiac risk factors</keyword>
  <keyword>memory</keyword>
  <keyword>cognition</keyword>
  <keyword>n-3 fatty acids</keyword>
  <keyword>fish oil</keyword>
  <keyword>EPA</keyword>
  <keyword>DHA</keyword>
  <keyword>seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the local epilepsy society, and from flyers posted in the epilepsy clinic at UCLA, and from referrals within the UCLA Department of Neurology</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>P L H</title>
          <description>Placebo, then Low Dose, then High Dose</description>
        </group>
        <group group_id="P2">
          <title>P H L</title>
          <description>Placebo, then High Dose, then Low Dose</description>
        </group>
        <group group_id="P3">
          <title>L H P</title>
          <description>Low Dose, then High Dose, then Placebo</description>
        </group>
        <group group_id="P4">
          <title>L P H</title>
          <description>Low Dose, then Placebo, then High Dose</description>
        </group>
        <group group_id="P5">
          <title>H L P</title>
          <description>High Dose, then Low Dose, then Placebo</description>
        </group>
        <group group_id="P6">
          <title>H P L</title>
          <description>High Dose, then Placebo, then Low Dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (10 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (10 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Intervention (10 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>16 Female, 8 Male</population>
      <group_list>
        <group group_id="B1">
          <title>Baseline</title>
          <description>The study began on Visit 1 when baseline data was collected and Intervention 1 was initiated.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.04" spread="10.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seizure Frequency</title>
        <description>Seizure frequency (seizures per day or seizures per month)</description>
        <time_frame>Study completion (42 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Corn Oil - 6 capsules per day</description>
          </group>
          <group group_id="O2">
            <title>Fish Oil Low Dose</title>
            <description>Fish Oil - 3 capsules per day Corn Oil - 3 capsules per day EPA+DHA = 1080 mg/day</description>
          </group>
          <group group_id="O3">
            <title>Fish OIl High Dose</title>
            <description>Fish Oil - 6 capsules per day EPA+DHA = 2160 mg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Seizure Frequency</title>
          <description>Seizure frequency (seizures per day or seizures per month)</description>
          <units>Seizures per Day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.655" spread="0.153"/>
                    <measurement group_id="O2" value="0.435" spread="0.097"/>
                    <measurement group_id="O3" value="0.631" spread="0.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>High Dose</title>
          <description>High Dose Fish Oil Intervention</description>
        </group>
        <group group_id="E2">
          <title>Low Dose</title>
          <description>Low Dose Fish Oil Intervention</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Corn Oil Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SUDEP</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death in Epilepsy</sub_title>
                <description>32 year old subject died after a seizure. Found supine on floor next to bed after likely seizure. Autopsy confirmed SUDEP, unrelated to participation in study or study supplement (Fish Oil). Reported to IRB and NIH immediately.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher M. DeGiorgio, MD</name_or_title>
      <organization>UCLA School of Medicine</organization>
      <phone>310-206-3753</phone>
      <email>cmd@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

